PMID- 29906743
OWN - NLM
STAT- MEDLINE
DCOM- 20181108
LR  - 20181108
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 61
DP  - 2018 Aug
TI  - Costunolide ameliorates lipoteichoic acid-induced acute lung injury via 
      attenuating MAPK signaling pathway.
PG  - 283-289
LID - S1567-5769(18)30268-6 [pii]
LID - 10.1016/j.intimp.2018.06.017 [doi]
AB  - Lipoteichoic acid (LTA)-induced acute lung injury (ALI) is an experimental model 
      for mimicking Gram-positive bacteria-induced pneumonia that is a refractory 
      disease with lack of effective medicines. Here, we reported that costunolide, a 
      sesquiterpene lactone, ameliorated LTA-induced ALI. Costunolide treatment reduced 
      LTA-induced neutrophil lung infiltration, cytokine and chemokine production 
      (TNF-alpha, IL-6 and KC), and pulmonary edema. In response to LTA challenge, 
      treatment with costunolide resulted less iNOS expression and produced less 
      inflammatory cytokines in bone marrow derived macrophages (BMDMs). Pretreatment 
      with costunolide also attenuated the LTA-induced the phosphorylation of p38 MAPK 
      and ERK in BMDMs. Furthermore, costunolide treatment reduced the phosphorylation 
      of TAK1 and inhibited the interaction of TAK1 with Tab1. In conclusion, we have 
      demonstrated that costunolide protects against LTA-induced ALI via inhibiting 
      TAK1-mediated MAPK signaling pathway, and our studies suggest that costunolide is 
      a promising agent for treatment of Gram-positive bacteria-mediated pneumonia.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Chen, Zhengxu
AU  - Chen Z
AD  - Department of Clinical Laboratory, The Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui Province, China; Department of Clinical 
      Laboratory, The Second People's Hospital of Hefei, Hefei, Anhui Province, China.
FAU - Zhang, Dan
AU  - Zhang D
AD  - Research Center for Cancer Precision Medicine, Department of Laboratory Medicine, 
      Bengbu Medical College, Bengbu, Anhui Province, China. Electronic address: 
      zhangdan_0117@163.com.
FAU - Li, Man
AU  - Li M
AD  - Department of Clinical Laboratory, The Second People's Hospital of Hefei, Hefei, 
      Anhui Province, China.
FAU - Wang, Baolong
AU  - Wang B
AD  - Department of Clinical Laboratory, The Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui Province, China. Electronic address: 
      wbl196555@163.com.
LA  - eng
PT  - Journal Article
DEP - 20180612
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Sesquiterpenes)
RN  - 0 (Teichoic Acids)
RN  - 4IK578SA7Z (costunolide)
RN  - 56411-57-5 (lipoteichoic acid)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 2.7.11.25 (MAP kinase kinase kinase 7)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Cells, Cultured
MH  - Chemical and Drug Induced Liver Injury/*drug therapy
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Gram-Positive Bacteria/*physiology
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Lipopolysaccharides
MH  - Lung/*drug effects/immunology/pathology
MH  - MAP Kinase Kinase Kinases/metabolism
MH  - Macrophages/*drug effects/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neutrophil Infiltration
MH  - Pneumonia, Bacterial/*drug therapy
MH  - Pulmonary Edema/*drug therapy
MH  - Sesquiterpenes/*therapeutic use
MH  - Signal Transduction
MH  - Teichoic Acids
OTO - NOTNLM
OT  - Acute lung injury
OT  - Costunolide
OT  - Lipoteichoic acid
OT  - Macrophage
OT  - TLR2
EDAT- 2018/06/16 06:00
MHDA- 2018/11/09 06:00
CRDT- 2018/06/16 06:00
PHST- 2017/12/24 00:00 [received]
PHST- 2018/05/22 00:00 [revised]
PHST- 2018/06/08 00:00 [accepted]
PHST- 2018/06/16 06:00 [pubmed]
PHST- 2018/11/09 06:00 [medline]
PHST- 2018/06/16 06:00 [entrez]
AID - S1567-5769(18)30268-6 [pii]
AID - 10.1016/j.intimp.2018.06.017 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2018 Aug;61:283-289. doi: 10.1016/j.intimp.2018.06.017. Epub 
      2018 Jun 12.